##### 



Exhibit 10.41
 ***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
 BiTE Research Collaboration Agreement
 Agreement Effective Date Micromet MedImmune Party Parties
 Recitals
 A.
 B.
 C.
 D.
  Agreement
 1. Definitions
  1.1 Affiliate
 1




---



##### 



1.2 Applicable Law
 1.3 Approved Collaboration Product
 1.4 BiTE Molecule
 1.5 BiTE Product
 1.6 BLA
 1.7 cGMP
 1.8 Clinical Trial Materials
 1.9 Collaboration Product
 1.10 Collaboration Target
 1.11 Collaboration Technology
 1.12 Commercial Process
 1.13 Commercialization Commercialize
 1.14 Commercially Reasonable Efforts
 2




---



##### 



1.15 Control ,
 1.16 Co-Promotion Option
 1.17 Development Activities
 1.18 Development Cost
 1.19 Development Plan
 1.20 EMEA
 1.21 Europe
 1.22 Excluded Target
 1.23 FDA
 1.24 FTE
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 3




---



##### 



1.25 FTE Rate 
 1.26 Fully-Burdened Manufacturing Cost
 1.27 IND
 1.28 Independent MedImmune Technology
 1.29 Independent Micromet Technology
 1.30 JDC
 1.31 Joint Collaboration Technology
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 4




---



##### 



1.32 JPT
 1.33 JPT Leader
 1.34 Know-How
 1.35 Licensed Technology
 1.36 MAA
 1.37 Major European Markets
 1.38 Marketing Approval
 1.39 MedImmune Collaboration Technology
 1.40 MedImmune Process Technology
 1.41 Micromet Collaboration Technology
 1.42 Net Profits
 1.43 Net Sales
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 5




---



##### 



1.44 Non-Proprietary Target
 1.45 Patents
 1.46 Phase I Clinical Trial
 1.47 Phase II Clinical Trial
 1.48 Pivotal Trial
 1.49 Proprietary Target
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 6




---



##### 



1.50 Qualified Sales Force
 1.51 Research Plan
 1.52 Single Chain Antibody
 1.53 Target
 1.54 Technology Acquisition Agreement
 1.55 Technology Acquisition Payments
 1.56 Territory
 1.57 Third Party
 1.58 Upstream Licensor
 1.59 Valid Claim
 1.60 [***] Patent
 2. Selection of Collaboration Targets
 2.1 Identification of Targets by MedImmune.
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 7




---



##### 



2.1.1 Selection Notice Selection Period Selection Notice
 2.1.2 Target Limitation
 2.2 Gatekeeping Process
 2.2.1 Exclusion Criteria Excluded Target
 2.2.2 Notification by Micromet
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 8




---



##### 



2.2.3 Change of Target Status
 (a)
 (b)
 3. Collaboration Governance for Collaboration Products
 3.1 Joint Development Committee
 3.1.1 Establishment of the JDC JDC
 3.1.2 Tasks of the JDC
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 9




---



##### 



3.1.3 JDC Meetings
 3.1.4 Meeting Minutes
 3.1.5 Decision Making
 (a)
 (b)
 (c)
 (d)
 3.2 Joint Project Team
 3.2.1 Establishment of the JPT JPT JPT Leader
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 10




---



##### 



3.2.2 Decision Making
 3.2.3 Research Plan Research Plan
 3.2.4 Development Plan Development Plan
 3.2.5 Reporting
 3.2.6 Agendas; Meetings; Minutes
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 11




---



##### 



4. Research and Development of Collaboration Products
 4.1 Preclinical Research and Development.
 4.1.1
 4.1.2
 4.2 Clinical Development of Collaboration Products binding to Proprietary Targets
 4.3 Clinical Development of Collaboration Products binding to Non-Proprietary Targets
 4.3.1
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 12




---



##### 



4.3.2
 4.3.3
 4.3.4 Passive Party
 4.4 Research and Development Costs.
 4.4.1 Research Plan
 (a)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 13




---



##### 



(b)
 (c)
 4.4.2 Development Plan
 4.5 Diligence
 4.5.1
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 14




---



##### 



4.5.2
 4.5.3
 4.6 Exchange of CMC Documentation
 4.7 Restrictions on Development and Commercialization of Licensed Products
 4.7.1
 4.7.2
 4.7.3
 5. Co-Promotion Option
 5.1 Grant and Exercise Co-Promotion Option
 15




---



##### 



Exercise Date
 5.2 Development Following Option Exercise
 5.3 Development Costs
 5.4 Co-Promotion Agreement
 5.4.1
 5.4.2 Dispute Resolution for Co-Promotion Terms
 (a) JAMS
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 16




---



##### 



(b) Support Memorandum Rebuttal
 (c) Selected
Agreement
 (d)
 5.4.3 Buy-Out of Co-Promotion Option
 5.4.4 Loss of Co-Promotion Rights
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 17




---



##### 



6. Reversion of Collaboration Products; Expiration of Collaboration
 6.1 Reversion of Products
 6.1.1 Reversion Triggers and Territories
 6.1.2 Continuation Notice Continuation Notice
 6.1.3 Licenses and Royalties
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 18




---



##### 



6.1.4
 6.2 Expiration of Collaboration
 6.2.1
 6.2.2
 7. Supply of Collaboration Product
 7.1 Clinical Supply of Collaboration Products
 7.2 Supply Price, Forecasting and Purchase Orders
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 19




---



##### 



7.3 Packaging, Shipping and Delivery
 7.4 Risk of Loss
 7.5 Invoice and Payment
 7.6 Warranties
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 20




---



##### 



Specifications Product Warranties
 7.7 Acceptance of Clinical Trial Materials Acceptance Period Rejection Notice Latent Defect
 7.8 Disputes Regarding Clinical Trial Materials
 7.8.1
 7.8.2
 7.8.3
 21




---



##### 



7.9 Remedies for Non-Conforming Clinical Trial Materials
 7.10 Audits and Inspections
 7.10.1
 7.10.2
 7.11 Commercial Supply of Collaboration Product
 7.11.1 Commercial Supply Agreement
 22




---



##### 



Commercial Supply Agreement
 7.11.2 Supply Price; Royalty
 (a)
 (b)
 (c)
 8. Transfer of Manufacturing Process
 8.1 Transfer Triggers
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 23




---



##### 



8.2 Manufacture During Process Transfer
 8.3 Technology Transfer
 8.4 Subsequent Process Transfer by Micromet
 9. Commercialization of Collaboration Products
 9.1 Commercialization Rights and Responsibilities
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 24




---



##### 



9.2 Diligence
 9.2.1
 9.2.2
 9.2.3
 9.2.4
 9.2.5 Adverse Drug Experiences
 9.3 Branding, Trademarks, Trade Dress, and Logos
 9.3.1
 9.3.2
 25




---



##### 



10. Ownership of Intellectual Property; Acquisition of Third Party Intellectual Property
 10.1 Ownership by Micromet
 10.2 Ownership by MedImmune
 10.3 Joint Ownership
 10.4 Further Acts
 10.5 Third Party Technology
 10.5.1 Consent
 (a)
 26




---



##### 



(b)
 (c)
 10.5.2 Terms and Maintenance
 10.5.3 Technology Acquisition Payments
 (a)
 (b)
 27




---



##### 



(c)
 11. License Grants
 11.1 Licenses granted by Micromet
 11.1.1
 11.1.2
 11.1.3
 11.1.4
 11.2 Licenses granted by MedImmune
 11.2.1
 28




---



##### 



11.2.2
 11.2.3
 11.2.4 mutatis mutandis
 11.2.5
 11.2.6
 29




---



##### 



11.3 Limitations on MedImmunes Ability to License
 11.4 Limitations on Micromets Ability to License
 11.5 Option for Exclusive License to [ ] Patent
 11.5.1 Grant of Option
 11.5.2 Financial Terms
 11.6 Bankruptcy Provision under German Law
 11.6.1
 11.6.2
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 30




---



##### 



11.7 Bankruptcy Provision under US Law Title 11
 11.8 First Offer
 11.9 Disclosure of Micromet Core Technology
 12. Prosecution, Enforcement and Defense of Patents
 12.1 Prosecution and Maintenance of Patents
 12.1.1
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 31




---



##### 



12.1.2
 12.1.3
 12.1.4
 12.1.5
 12.2 Enforcement of Patents
 12.2.1 Notice
 12.2.2 Enforcement Actions for Micromet Technology
 (a)
 (b)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 32




---



##### 



12.2.3 Enforcement Actions for MedImmune Technology
 12.2.4 Cooperation; Damages
 12.3 Third Party Patents
 13. Fees and Payments
 13.1 Development Milestones
 33




---



##### 



Milestone Event
    
    Milestone Payment1. Upon achievement of the preclinical proof of concept criteria, as
established unanimously by the JDC and set forth in the applicable
Research Plan
    
    US$[***]2. Upon filing of the first IND in the United States
    
    US$[***]3. First patient enrolled in first Pivotal Trial for the United
States
    
    US$[***]4. Filing of first BLA in the United States
    
    US$[***]5. Approval of first BLA in the United States
    
    US$[***]6. Approval of first MAA in Europe
    
    US$[***]*
 
 *
    
    This milestone payment is waived by Micromet if Micromet or a Third Party licensee of Micromet is
the sponsor of such MAA pursuant to clause (b) of Section 4.2. 13.2 Royalties
 13.2.1 Royalty Rates
 (a)
 (b)
 (c)
 (d)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 34




---



##### 



(e) Combination Product
 (f)
 13.2.2 Royalty Term
 (a)
 (b)
 (c)
 13.2.3 Royalty Adjustments
 (a)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 35




---



##### 



(b)
 13.3 Profit Sharing
 14. Payment Terms
 14.1 Payment Method The Wall Street Journal
 14.2 Payment Schedules; Reports
 14.3 Records Retention; Audit
 14.3.1 Record Retention
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 36




---



##### 



14.3.2 Audit
 14.3.3 Payment of Additional Amounts
 14.3.4 Confidentiality
 15. Confidentiality
 15.1 Definition Confidential Information
 15.2 Exclusions
 15.2.1
 (a)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 37




---



##### 



(b)
 (c)
 (d)
 (e)
 15.3 Disclosure and Use Restriction
 15.4 Authorized Disclosure
 (a)
 (b)
 (c)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 38




---



##### 



(d)
 (e)
 (f)
 15.5 Terms of Agreement to be Maintained in Confidence
 16. Public Communications
 16.1 General Provisions
 16.2 Use of Name
 16.3 Press Releases
 16.3.1 Proposed Disclosure
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 39




---



##### 



16.3.2
 16.3.3
 16.4 Publications
 17. Term and Termination
 17.1 Term Term
 17.2 Breach
 17.2.1
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 40




---



##### 



17.2.2
 17.3 Voluntary Termination
 18. Effects of Termination
 18.1 Continuation of Development and Commercialization
 18.1.1
 18.1.2
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 41




---



##### 



(a)
 (b)
 (c)
 (d)
 18.1.3
 (a)
 (b)
 (c)
 (d)
 (e)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 42




---



##### 



18.1.4
 18.2 Effect of Expiration on Intellectual Property
 18.3 Effects of Termination on Licenses
 18.3.1
 18.3.2
 18.3.3
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 43




---



##### 



18.4 Accrued Rights
 18.5 Survival
 18.6 Inventory
 18.7 Proprietary Target Restrictions
 18.8 Sublicenses
 19. Indemnification and Insurance
 19.1 Indemnification of Micromet Micromet Indemnitee
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 44




---



##### 



Losses
 19.2 Indemnification of MedImmune
 19.3 Notice of Claim
 19.4 Control of Defense
 45




---



##### 



19.5 Right to Participate in Defense
 19.6 Settlement
 19.7 Cooperation
 19.8 Insurance
 20. Representations and Warranties
 20.1 Mutual Representations and Warranties
 46




---



##### 



20.1.1
 20.1.2
 20.1.3
 20.2 Additional Representations and Warranties of Micromet
 (a)
 (b)
 (c)
 (d)
 (e)
 (f)
 (g)
 (h)
 47




---



##### 



20.3 Schedule of Exceptions
 20.4 Additional Representations and Warranties of MedImmune
 21. Disclaimer; Limitation of Liability
 21.1 Disclaimer of Warranty
 21.2 Limitation of Liability
 48




---



##### 



22. Miscellaneous
 22.1 Force Majeure
 22.2 Assignment
 22.2.1
 22.2.2
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 49




---



##### 



22.3 Severability
 22.4 Governing Law; Dispute Resolution
 22.4.1
 22.4.2
 22.4.3
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 50




---



##### 



22.4.4
 22.5 Notices
   
  
  
    51




---



##### 



22.6 Entire Agreement; Modifications
 22.7 Relationship of the Parties
 22.8 Waiver
 22.9 Counterparts
 22.10 No Benefit to Third Parties
 52




---



##### 



22.11 Further Assurance
 22.12 English Language
 22.13 Construction
 [Remainder of this page is left blank intentionally]
 53




---



##### 



In Witness Whereof
 Micromet AG
    
    MedImmune, Inc.By: /s/ Christian Itin
    
    By: /s/ David M. MottName: Christian Itin
    
    Name: David M. MottTitle: Chief Business Officer
    
    Title: CEOBy: /s/ G.K. MirowName: G.K. MirowTitle: Chief Financial Officer
 [Signature Page to the BiTE Research Collaboration Agreement]
 54




---



##### 



Exhibit A-1
 Issued Patents and Published Patent Applications of Micromet
 Patent / ApplicationCountry
    
    Title of Application
    
    Number
    
    Comment/Status[***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1




---



##### 



Patent / ApplicationCountry
    
    Title of Application
    
    Number
    
    Comment/Status[***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 2




---



##### 



Exhibit A-2
 Issued Patents and Published Patent Applications  licensed by Micromet
 Application
    
    Application
    
    
    
    
    
    
    
    Patent
    
    Date ofNumber
    
    Filing Date
    
    Country
    
    Title of Application
    
    Status
    
    Number
    
    Grant[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1




---



##### 



Application
    
    Application
    
    
    
    
    
    
    
    Patent
    
    Date ofNumber
    
    Filing Date
    
    Country
    
    Title of Application
    
    Status
    
    Number
    
    Grant[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 2




---



##### 



Date ofApplication
    
    Application
    
    
    
    
    
    Application
    
    Patent
    
    PatentNumber
    
    Filing Date
    
    Country
    
    Title of Application
    
    Status
    
    Number
    
    Grant[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 3




---



##### 



Date ofApplication
    
    Application
    
    
    
    
    
    Application
    
    Patent
    
    PatentNumber
    
    Filing Date
    
    Country
    
    Title of Application
    
    Status
    
    Number
    
    Grant[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 4




---



##### 



Country
    
    Appln.-No.
    
    Patent-No.
    
    Expiry Date
    
    Status
    
    Type[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
  Country
    
    Appln.-No.
    
    Patent-No.
    
    Expiry Date
    
    Status
    
    Type[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 5




---



##### 



Country
    
    Appln.-No.
    
    Patent-No.
    
    Expiry Date
    
    Status
    
    Type[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
  
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 6




---



##### 



Exhibit B
 Net Profits
        
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1




---



##### 



***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 2




---



##### 



Exhibit C
 List of Proprietary Targets
  
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1




---



##### 



Exhibit D
 List of Technology Acquisition Agreements
 
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1




---



##### 



Exhibit E
 [***] Patent
 Country
    
    Appln.-No.
    
    Patent-No.
    
    Expiry Date
    
    Status
    
    Type[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1




---



##### 



Exhibit F
 List of Excluded Targets
 
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1